Phase i dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours

European Journal of Cancer

Volumn 49, Issue 1, 2013, Pages 17-24

  Van Cutsem, Eric ^a   Khayat, David ^b   Verslype, Chris ^a   Billemont, Bertrand ^c   Tejpar, Sabine ^a   Meric, Jean Baptiste ^d   Soussan Lazard, Karen ^e   Assadourian, Sylvie ^e   Cartot Cotton, Sylvaine ^e   Rixe, Olivier ^f  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Hospital Cochin ^*  (France)

^d Center Medical of Bligny   (France)

^e SANOFI   (France)

^f UNIVERSITY OF CINCINNATI   (United States)

Author keywords

5 Fluorouracil; Aflibercept; Irinotecan; Phase I study; Solid tumours

Indexed keywords

AFLIBERCEPT; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CREATININE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BONE NECROSIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL TUMOR; CREATININE BLOOD LEVEL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; FATIGUE; FEMALE; HUMAN; HYPERTENSION; IMMUNOGENICITY; KIDNEY BIOPSY; LIVER FUNCTION TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEPHROTIC SYNDROME; NEUTROPENIA; OPEN STUDY; OVARY TUMOR; PAROTID GLAND TUMOR; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; SOLID TUMOR; STOMATITIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASMS; RECOMBINANT FUSION PROTEINS; YOUNG ADULT;

EID: 84871448485     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.07.007     Document Type: Article

References (16)

1. N. Ferrara Vascular endothelial growth factor Arterioscler Thromb Vasc Biol 29 2009 789 791
2. A. Veeravagu, A.R. Hsu, and W. Cai Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy Recent Pat Anticancer Drug Discov 2 2007 59 71 (Pubitemid 46723152)
3. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
4. R.J. Motzer, M.D. Michaelson, and B.G. Redman Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 2006 16 24 (Pubitemid 46630489)
5. B.I. Rini Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions Clin Cancer Res 13 2007 1098 1106 (Pubitemid 46424048)
6. J. Holash, S. Davis, and N. Papadopoulos VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci USA 99 2002 11393 11398 (Pubitemid 34920936)
7. H.M. Verheul, H. Hammers, and K. van Erp Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model Clin Cancer Res 13 2007 4201 4208 (Pubitemid 47105984)
8. A.T. Byrne, L. Ross, and J. Holash Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model Clin Cancer Res 9 2003 5721 5728 (Pubitemid 37499496)
9. M. Fukasawa, and M. Korc Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines Clin Cancer Res 10 2004 3327 3332 (Pubitemid 38685437)
10. J. Huang, J.S. Frischer, and A. Serur Regression of established tumors and metastases by potent vascular endothelial growth factor blockade Proc Natl Acad Sci USA 100 2003 7785 7790 (Pubitemid 36760047)
11. A.C. Lockhart, M.L. Rothenberg, and J. Dupont Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors J Clin Oncol 28 2010 207 214
12. W.P. Tew, M. Gordon, and J. Murren Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors Clin Cancer Res 16 2010 358 366
13. H. Izzedine, I. Brocheriou, G. Deray, and O. Rixe Thrombotic microangiopathy and anti-VEGF agents Nephrol Dial Transplant 22 2007 1481 1482
14. J.S. Rudge, J. Holash, and D. Hylton Inaugural Article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade Proc Natl Acad Sci USA 104 2007 18363 18370 (Pubitemid 350210713)
15. C.J. Kuo, F. Farnebo, and E.Y. Yu Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer Proc Natl Acad Sci USA 98 2001 4605 4610 (Pubitemid 32295023)
16. L.G. Presta, H. Chen, and S.J. O'Connor Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 1997 4593 4599 (Pubitemid 27441066)